| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2004 | US20040077557 Systemic or topical bacterial infections; erythromycin A derivatives |
| 04/22/2004 | US20040077556 Epigallocatechin gallate, caffeine and tyrosine |
| 04/22/2004 | US20040077554 Topoisomerase I inhibitors; such as 2,3-methylenedioxy-6-hydroxymethyl-9-hydroxy-12-(beta-D-glucopyranosyl) -6,7,12,13-tetrahydroindolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7-dione |
| 04/22/2004 | US20040077553 Such as 1-(((alpha-propanoyloxybutoxy)carbonyl)aminomethyl)-1-cyclohexane acetic acid; ability to cross blood brain barrier; sustained release |
| 04/22/2004 | US20040077552 Inflammation-inhibiting compounds |
| 04/22/2004 | US20040077551 NS3 protease inhibitors; quinoline derivatives |
| 04/22/2004 | US20040077550 One pot process; forming acryloyl-guanidino derivatives |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077539 Stimulating growth of lactic acid producing bacteria in gastrointestinal tract; enriched whey protein concentrate |
| 04/22/2004 | US20040077533 Methods and compositions for treating bacterial infections and diseases associated therewith |
| 04/22/2004 | US20040077532 Aglyco products and methods of use |
| 04/22/2004 | US20040077525 Novel treatment |
| 04/22/2004 | US20040077524 Method for selectively inhibiting fungal growth |
| 04/22/2004 | US20040077232 Pharmaceutical compositions |
| 04/22/2004 | US20040077087 DNA damaging agents in combination with tyrosine kinase inhibitors |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040077031 Using the manganese form of the enzyme and therefore, the advantage of identifying potent inhibitors that might not show activity in cellular systems because the wrong metal cofactor is used |
| 04/22/2004 | US20040077029 Human protooncogene and protein encoded therein |
| 04/22/2004 | US20040077002 Useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty; atherosclerosis |
| 04/22/2004 | US20040077000 Using cynomologous monkey P-glycoprotein nucleic acids and polypeptides in determining bioavailability of drugs and for screening for inhibitors of cynomologous P-glycoprotein |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076968 Method for detecting pre-disposition to hepatotoxicity |
| 04/22/2004 | US20040076956 Oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with DNA repair which are directed against the sequence; ascertaining genetic and/ or epigenetic parameters of DNA repair genes |
| 04/22/2004 | US20040076699 Mixtures of tannins comprising emblicanin A, emblicanin B, pedunculagin and punigluconin, dispersants and optiaonally sunscreen agents, used as cosmetics having improved skin feel |
| 04/22/2004 | US20040076698 Drugs comprising plant extracts used for prevention amyloid formation, deposition or accumulation |
| 04/22/2004 | US20040076695 EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 04/22/2004 | US20040076692 Mixtures of xanthine oxidase inhibitors and free radical scavangers, used as antiischemic agents or for prophylaxis of cardiovascular disorders |
| 04/22/2004 | US20040076691 Anti-inflammatory formulations |
| 04/22/2004 | US20040076690 Mixtures of phenolic alcohols such as zingerone and flavors such as ethyl vanillin, administered to mammals as dietetics |
| 04/22/2004 | US20040076679 Gel delivery vehicles for anticellular proliferative agents |
| 04/22/2004 | US20040076678 Opthalmic solution |
| 04/22/2004 | US20040076675 Composition improved in solubility or oral absorbability |
| 04/22/2004 | US20040076673 Oral pharmaceutical composition containing a block copolymer |
| 04/22/2004 | US20040076672 For treating cancer and other angiogenic-dependent diseases, and more specifically, to compositions comprising anti-angiogenic factors and polymeric carriers, stents which have been coated with such compositions |
| 04/22/2004 | US20040076671 Methods and compositions for topical wound treatment |
| 04/22/2004 | US20040076669 Tramadol-based medicament |
| 04/22/2004 | US20040076668 Comprises PDE4D inhibitor, or pharmaceutically acceptable salt thereof, preferably (R)-2-(4-(((2-(benzo(1,3)dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-3-fluoro-phenoxy)-propionic acid |
| 04/22/2004 | US20040076667 Sustained release pharmaceutical composition containing metformin hydrochloride |
| 04/22/2004 | US20040076665 Modified release oral dosage form |
| 04/22/2004 | US20040076664 Chewable, soft gel, high potency vitamins and method of manufacture |
| 04/22/2004 | US20040076658 Readily dispersible dietary fiber composition |
| 04/22/2004 | US20040076653 Method for inducing production of fibrous organic tissue |
| 04/22/2004 | US20040076648 Antidepressant, an n-methyl-aspartic acid receptor antagonist, a lipophilic component, water and a surfacant; oil in water emulsion |
| 04/22/2004 | US20040076645 Ghrelin-carrier conjugates |
| 04/22/2004 | US20040076632 DNA vaccine against feline immunodeficiency virus |
| 04/22/2004 | US20040076628 Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 04/22/2004 | US20040076609 Chemokine receptors (CCR5); for lowering HIV-RNA plasma levels |
| 04/22/2004 | US20040076607 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/22/2004 | US20040076601 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 04/22/2004 | US20040076590 Comprise therapeutically effective amounts of d-limonene |
| 04/22/2004 | US20040076589 Comprises albuterol/insulin; eliminates need for injections |
| 04/22/2004 | US20040076588 Inhalable epinephrine |
| 04/22/2004 | US20040076582 Comprises spherical/micronized polyvinyl alcohol particle containing radioactive species; monoclonal antibodies |
| 04/22/2004 | US20040074447 Methods of reducing incidence of stillborn pigs by using progesterone receptor antagonists |
| 04/22/2004 | DE10247037A1 Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2531056A1 Therapeutic combination of carnitine and antioxidant polyphenols |
| 04/22/2004 | CA2501970A1 Gelled laxative compositions |
| 04/22/2004 | CA2501967A1 Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity |
| 04/22/2004 | CA2501947A1 Azaindole derivatives as inhibitors of p38 kinase |
| 04/22/2004 | CA2501938A1 Compounds, compositions, and methods |
| 04/22/2004 | CA2501901A1 Anticancer compounds |
| 04/22/2004 | CA2501803A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 04/22/2004 | CA2501801A1 Sulfonylbenzodiazepinone acetamides as bradykinin antagonists |
| 04/22/2004 | CA2501767A1 Mixture compositions for controlling ectoparasites |
| 04/22/2004 | CA2501752A1 Compositions, organisms and methodologies employing a novel human kinase |
| 04/22/2004 | CA2501742A1 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 04/22/2004 | CA2501685A1 Compounds for modulation of cholesterol transport |
| 04/22/2004 | CA2501625A1 X-nitro compounds, pharmaceutical compositions thereof and uses therof |
| 04/22/2004 | CA2501620A1 Treatment of aml |
| 04/22/2004 | CA2501614A1 Mucoadhesive tetracycline formulations |
| 04/22/2004 | CA2501611A1 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
| 04/22/2004 | CA2501540A1 Methods and compositions for providing glutamine |
| 04/22/2004 | CA2501491A1 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease |
| 04/22/2004 | CA2501348A1 Treatment of dementia and parkinson's disease |
| 04/22/2004 | CA2501347A1 Methods for the treatment of neurodegeneration |
| 04/22/2004 | CA2501345A1 Gastro-retentive levodopa delivery form |
| 04/22/2004 | CA2501318A1 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| 04/22/2004 | CA2501082A1 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 04/22/2004 | CA2501055A1 Novel betamimetics with extended duration of action, method for production and use thereof as medicaments |
| 04/22/2004 | CA2501043A1 Method of inhibiting angiogenesis |
| 04/22/2004 | CA2500922A1 Pharmaceutical compositions for treatment of parkinson's disease |
| 04/22/2004 | CA2500919A1 Compositions and methods for treating sexual dysfunction |
| 04/22/2004 | CA2500906A1 Combination therapy with gemcitabine and zd6126 |
| 04/22/2004 | CA2500742A1 Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis |
| 04/22/2004 | CA2500582A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| 04/22/2004 | CA2500385A1 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/22/2004 | CA2500375A1 Stabilized pharmaceutical composition containing basic excipients |
| 04/22/2004 | CA2500368A1 Inhibition of src for treatment of reperfusion injury related to revascularization |
| 04/22/2004 | CA2500310A1 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 04/22/2004 | CA2499682A1 Epo d + 5-fu/gemcitabine |
| 04/22/2004 | CA2499677A1 Classes of compounds that interact with gpcrs |
| 04/22/2004 | CA2499324A1 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 04/22/2004 | CA2499290A1 Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility |
| 04/22/2004 | CA2498938A1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 04/22/2004 | CA2498488A1 Solid particulate antifungal compositions for pharmaceutical use |
| 04/22/2004 | CA2482013A1 Process for preparing tannate tablet capsule or other solid dosage forms |
| 04/22/2004 | CA2465860A1 Methods and compositions for therapeutic use of rna interference |
| 04/22/2004 | CA2421887A1 Baicalein and baicalein analogs and uses thereof |
| 04/21/2004 | EP1411129A1 Process for producing fat comprising triglyceride containing highly unsaturated fatty acid |